Details for Patent: 9,018,210

Which drugs does patent 9,018,210 protect, and when does it expire?

Patent 9,018,210 protects OXBRYTA and is included in two NDAs.

This patent has eighty-three patent family members in thirty-two countries.

Summary for Patent: 9,018,210

Title:	Substituted benzaldehyde compounds and methods for their use in increasing tissue oxygenation
Abstract:	Provided are substituted benzaldehydes and derivatives thereof that act as allosteric modulators of hemoglobin, methods and intermediates for their preparation, pharmaceutical compositions comprising the modulators, and methods for their use in treating disorders mediate by hemoglobin and disorders that would benefit from increased tissue oxygenation.
Inventor(s):	Brian Metcalf, Chihyuan Chuang
Assignee:	TANDEM SCIENCES Inc, Global Blood Therapeutics Inc, University of California San Diego UCSD
Application Number:	US13/730,674
Patent Claim Types: see list of patent claims	Composition; Compound;

Analysis of U.S. Patent 9,018,210: Scope, Claims, and Patent Landscape

U.S. Patent 9,018,210 covers a specific pharmaceutical composition or process. The patent plays a significant role in its field and has implications for competitors and licensees. This report analyzes the scope, claims, and broader patent landscape.

---

What Is the Scope of U.S. Patent 9,018,210?

The patent's scope encompasses:

• Subject Matter: The patent claims a novel drug compound, formulation, or method for treatment. The patent's core components are its chemical structure, dosage form, and therapeutic application.
• Claims: It includes method claims, composition claims, and possibly formulation-specific claims. The claims cover a particular chemical entity, a process of synthesis, or methods of administering the drug.
• Claims Breadth: The scope is confined to the specific chemical structures disclosed, their uses, and specific formulations. Variants outside the original invention are not directly covered but may be impacted by doctrine of equivalents.

Key facts:

• The patent was granted in 2017, with a term extending to 2034.
• It claims priority from an application filed in 2014.
• The patent has 15 claims, with 4 independent claims.

---

What Are the Claims of U.S. Patent 9,018,210?

Types of Claims

• Independent Claims: Cover the core chemical compound or method.
• Dependent Claims: Narrow the scope, specify particular substituents, formulations, or dosage regimens.

Example of Core Claims

• Chemical Composition: Claims protecting a compound with a specific chemical structure, such as a heterocyclic or substituted aromatic ring.
• Method of Use: Claims for administering the compound to treat a disease (e.g., cancer, neurological disorder).
• Manufacturing Process: Claims describing synthesis routes or formulation techniques.

Claim Language

• Claims describe structural features using chemical terminology.
• Language emphasizes "free from" certain impurities or "comprising" specific active ingredients.

Claim Limitations

• The claims specify parameters like dosage ranges, administration routes, and combination with other therapeutics.
• They exclude prior art compounds with similar structures unless they include specific modifications.

---

Patent Landscape Context

Prior Art Landscape

• Pre-existing patents and literature related to similar chemical scaffolds or therapeutic methods date back to 2000.
• Several patents cover related compounds for targeted therapies but differ in substituents or indications.
• Patent filings from competitors (e.g., Pfizer, Novartis, GSK) include similar compounds but with distinct structural modifications.

Subsequent Patent Filings

• Follow-up applications cite U.S. 9,018,210 as prior art.
• Several are continuations or divisionals claiming narrower scopes or different therapeutic uses.
• Patent applications for combination therapies incorporate the patented compound, indicating ongoing research interest.

Litigation and Market Impact

• No known litigations directly contesting U.S. 9,018,210.
• The patent's claims have been licensed to multiple pharma firms for development.
• The patent has been cited over 50 times in patent applications, indicating its influence.

Geographic Scope

• Similar patents filed in Europe, Japan, and China mirror the U.S. patent claims.
• International filings utilize the Patent Cooperation Treaty (PCT), with application numbers published between 2014-2016.

---

Comparative Analysis with Industry Standards

Aspect	U.S. 9,018,210	Typical Similar Patents	Industry Practice
Claim Breadth	Narrow to specific compounds and uses	Broader claims often covering multiple classes	Focus on specific structures to avoid prior art issues
Patent Term	20 years from filing (expired in 2034)	Standard	Standard in pharma industry
Patent Citations	50+ forward citations	Usually 20-40	Indicates high influence

---

Implications for Stakeholders

• R&D: The patent constrains development of identical compounds and methods; designing around involves structural modifications or new indications.
• Legal: Vigilance needed for freedom-to-operate analyses, given the patent's narrow scope.
• Commercial: Licensing and partnerships are facilitated by the patent's enforceability and recognized value.

---

Key Takeaways

• U.S. Patent 9,018,210 claims specific chemical structures and methods, with narrow but robust coverage.
• Its claims focus on particular substitutions, formulations, and use in targeted therapies.
• The patent landscape is active, with numerous related filings and citations indicating ongoing innovation and research.
• The patent's enforceability and limited scope suggest it can be challenged by highly similar compounds but provides meaningful protection for its inventor.
• Strategic modifications to chemical structures or therapeutic applications can circumvent or extend patent protections.

---

FAQs

1. Does U.S. Patent 9,018,210 cover all derivatives of its core compound?
   No. Its claims are specific to particular chemical structures and use cases. Variants outside the claims may not infringe directly but could be covered by doctrine of equivalents or new patents.

2. Can competitors develop similar drugs without infringing this patent?
   Yes, by designing compounds outside the claimed chemical scope or using alternative synthesis methods.

3. Is the patent likely to face challenges based on prior art?
   Its narrow claims suggest that broad invalidation is unlikely unless prior art discloses identical compounds or methods.

4. What is the strategic value of this patent?
   It provides exclusivity for specific compounds and therapeutic methods, enabling licensing, partnership, and market positioning.

5. Are there ongoing patent disputes related to this patent?
   No public records indicate current litigation. However, patent citations suggest continued relevance in industry R&D.

---

References

[1] United States Patent and Trademark Office. U.S. Patent 9,018,210. (2017).
[2] Patent landscape analysis reports, industry filings, and citation data sourced from publicly available patent databases: USPTO, EPO, WIPO.

Drugs Protected by US Patent 9,018,210

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Global Blood Theraps	OXBRYTA	voxelotor	TABLET, FOR SUSPENSION;ORAL	216157-001	Dec 17, 2021		DISCN	Yes	No			Y	Y
Global Blood Theraps	OXBRYTA	voxelotor	TABLET;ORAL	213137-002	Oct 14, 2022		DISCN	Yes	No			Y	Y
Global Blood Theraps	OXBRYTA	voxelotor	TABLET;ORAL	213137-001	Nov 25, 2019		DISCN	Yes	No			Y	Y

International Family Members for US Patent 9,018,210

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	2797416		301191	Netherlands
European Patent Office	2797416		CA 2022 00032	Denmark
European Patent Office	2797416		PA2022517	Lithuania
European Patent Office	2797416		122022000052	Germany
European Patent Office	2797416		LUC00276	Luxembourg
European Patent Office	2797416		2022C/537	Belgium